{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-010977","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.663251+00:00","generated_at":"2026-05-24T10:59:32.958178+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Kairos Pharma publishes study showing CD105 blockade restores osimertinib sensitivity in NSCLC","bullets":["Study in Drug Resistance Updates shows CD105 upregulation drives resistance to EGFR-targeted therapy osimertinib.","Preclinical models: ENV105 (carotuximab) combined with osimertinib restored drug sensitivity via metabolic reprogramming.","CEO states CD105 is a central resistance mechanism across prostate, breast, colon, and lung cancers.","ENV105 currently in Phase 2 for castrate-resistant prostate cancer and Phase 1 for lung cancer.","Global NSCLC treatment market projected to reach $45B by 2030; drug resistance remains a major challenge."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-010977","json":"https://secwatch.observer/filing/0001493152-25-010977.json","markdown":"https://secwatch.observer/filing/0001493152-25-010977.md","text":"https://secwatch.observer/filing/0001493152-25-010977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225010977/0001493152-25-010977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225010977/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:59:32.958178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}